Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AmnioExCel in Venous Leg Ulcerations
NCT02929056Phase 4Terminated
- Sponsor
- Prisma Health
- Start
- Feb 2017
- Primary completion
- Sep 2018
- Modality
- Tissue Cells, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of biological amniotic membrane in venous leg ulcer (VLU) (2 arms), sponsored by Prisma Health. Primary endpoint: Change in Wound Area at 12 weeks. Started Feb 2017; status: terminated.
02
Drugs
biological amniotic membrane
03
Conditions
venous leg ulcer (VLU)
Beyond the preview
Go deeper on NCT02929056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929056.